BioMarin

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BioMarin and other ETFs, options, and stocks.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,401

Employees3,401

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,401

Employees3,401

BMRN Key Statistics

Market cap

15.82B

Market cap15.82B

Price-Earnings ratio

75.58

Price-Earnings ratio75.58

Dividend yield

—

Dividend yield—

Average volume

2.29M

Average volume2.29M

High today

$83.98

High today$83.98

Low today

$80.50

Low today$80.50

Open price

$81.07

Open price$81.07

Volume

1.83M

Volume1.83M

52 Week high

$99.56

52 Week high$99.56

52 Week low

$76.02

52 Week low$76.02

BMRN News

Simply Wall St 2d

BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Last week, you might have seen that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its first-quarter result to the market. The early response was not posit...

Yahoo Finance 5d

Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc - Yahoo Finance

Robust portfolio of rare-disease therapies with a focus on genetic discovery. Strategic positioning with recent approvals of Roctavian in Europe and the US. C...

TipRanks 6d

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Pipeline and key...

Analyst ratings

70%

of 30 ratings

Buy

70%

Hold

30%

Sell

More BMRN News

Yahoo Finance 6d

BioMarin Pharmaceutical Inc. Q1 2024 Earnings Call Transcript - Yahoo Finance

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript April 24, 2024 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported E...

Simply Wall St 6d

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Simply Wall St

Last week, you might have seen that BioMarin Pharmaceutical Inc. ( ) released its first-quarter result to the market. The early response was not positive, with...

TipRanks 6d

BioMarin price target lowered to $89 from $91 at Canaccord

Canaccord analyst Whitney Ijem lowered the firm’s price target on BioMarin to $89 from $91 and keeps a Hold rating on the shares. The firm noted investor focus...

Simply Wall St 6d

BioMarin Pharmaceutical First Quarter 2024 Earnings: EPS Beats Expectations

BioMarin Pharmaceutical (NASDAQ:BMRN) First Quarter 2024 Results Key Financial Results Revenue: US$648.8m (up 8.8% from 1Q 2023). Net income: US$88.7m (up 74...

Seeking Alpha 6d

BioMarin stock falls 9% in wake of Q1 report, pipeline updates

Shares of BioMarin (BMRN) were down 9% in afternoon trading Thursday, the day after the company released a Q1 revenue report that fell short of expectations and...

Benzinga 6d

Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings) - Biomarin Pharmaceutical - Benzinga

Loading... Loading... In the preceding three months, 8 analysts have released ratings for Biomarin Pharmaceutical BMRN, presenting a wide array of perspectives...

Yahoo Finance 6d

BioMarin Beats on Q1 Earnings, Voxzogo Drives Sales - Yahoo Finance

BioMarin Pharmaceutical Inc. BMRN reported first-quarter 2024 adjusted earnings per share of 71 cents, beating the Zacks Consensus Estimate of 60 cents. The rep...